Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Halda Therapeutics Opco Inc. has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 3 actions are split among 3 distinct examiners and 3 distinct art units. SEITZ, ANTHONY JOSEPH is the busiest examiner for the portfolio with 1 busiest examiner pending action. Since there are 3 pending office actions and 3 distinct examiners, the workload is distributed evenly, with each examiner handling exactly one matter.
This distributed workload across 3 distinct art units indicates that the company's current biotechnology filings are diverse in their technical classification. Because each of the 3 pending office actions is assigned to a different distinct examiner, there is no opportunity to leverage a single examiner's familiarity across multiple applications. SEITZ, ANTHONY JOSEPH, as the busiest examiner with 1 busiest examiner pending action, represents a single component of the active prosecution effort. Practitioners must prepare for unique examination styles, as the 3 distinct examiners operate independently across their respective 3 distinct art units. The Biotechnology & Pharmaceuticals portfolio requires managing these matters without the benefit of examiner consolidation.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (67%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEITZ, ANTHONY JOSEPH | 1 | 67.8% | +27.5% |
| SHAMEEM, GOLAM M | 1 | 86.7% | +15.9% |
| BURKETT, DANIEL JOHN | 1 | 63.4% | +33.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18696722 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | SHAMEEM, GOLAM M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18696622 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | SEITZ, ANTHONY JOSEPH | — |
| 18696722 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | SHAMEEM, GOLAM M | — |
| 18696145 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | BURKETT, DANIEL JOHN | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1621 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18696622 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | SEITZ, ANTHONY JOSEPH | 1629 | §102§103§112DP | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18696722 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | SHAMEEM, GOLAM M | 1621 | §112 | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18696145 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | BURKETT, DANIEL JOHN | 1624 | §112 | Non-Final OA | — | Pending | Mar 27, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHalda Therapeutics Opco Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Anthony Joseph Seitz has the most, with 1 of Halda Therapeutics Opco Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
